SSY Group Limited (02005.HK): Calcium Levofolinate for Injection Approved, Deemed to Have Passed Consistency Evaluation

NewTimeSpace · 2026/03/06 13:13 · By Zeyu Wu

NewTimeSpace:SSY Group Limited (02005.HK) announced that it has obtained the drug production registration approval from the National Medical Products Administration (NMPA) for Calcium Levofolinate for Injection (25mg). The product is classified as a Class 3 chemical drug and is deemed to have passed the consistency evaluation. It is mainly used for the treatment of gastric cancer and colorectal cancer.

NewTimeSpace: SSY Group Limited (02005.HK) issued a voluntary announcement on March 6, 2026, disclosing the latest progress in its product development.

According to the announcement, the Group has obtained the drug production registration approval from the National Medical Products Administration of China for Calcium Levofolinate for Injection (25mg). The product is a Class 3 chemical drug and is deemed to have passed the consistency evaluation.

Calcium levofolinate is mainly used in combination with 5-fluorouracil for the treatment of gastric cancer and colorectal cancer. The approval marks the official start of production of this product and will further enrich the Group's product pipeline in the oncology field.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.

Tags：

SSY Group 02005.HK drug production registration approval